Individuals Discontinuing Anti-Obesity Medications Gain Back Weight at a Quadrupled Rate Compared to Those on Conventional Diets

Fresh analysis reveals that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop conventional diet and exercise programs.

Findings released in a leading medical journal points out that while overweight people can lose substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals using such drugs should be aware of the risk of fast weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.

This pace of recovery suggests a return to starting mass within about one and a half years.

Comparing Therapies

The analysis, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.

The team emphasize that people who shed pounds through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.

Explaining the Rapid Regain

Experts suggest the mechanism of the injections explains the amplified rebound.

GLP-1 drugs mimic a natural hormone called GLP-1, which controls feelings of fullness.

"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication leads to appetite is unsuppressed, making excessive eating much more probable."

A Lifelong Condition?

Health authorities recommend the injections for people with obesity-related health risks, alongside recommended lifestyle changes.

A number of clinicians say that, considering the high risk of weight regain, the treatment might need to be life-long.

This opinion is supported by drug manufacturers, who state that the results "underscore the chronic nature of obesity," similar to managing diseases like diabetes.

Patient Testimonies

People who have come off the medication report a intense return of hunger.

"I experienced a switch flipping and you become extremely hungry," said a patient.

The struggle is compounded if patients have not developed sustainable lifestyle or habit changes during therapy.

Widespread Adoption

Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is higher among women compared to men.
• The middle-aged age group shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

In conclusion, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and maintained weight loss hinges on combined lifestyle management.